Kuiper, Justine L <br/><br/>
Rationale and study design of the IRENE-trial (NVALT-16): a phase II trial to evaluate iressa rechallenge in advanced NSCLC patients with an activating EGFR mutation who responded to an EGFR-TKI used as first-line or previous treatment.  [electronic resource] 

 -  Clinical lung cancer  Jan 2015 
 - 60-6 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>1938-0690 
<br/><br/><label>Standard No.: </label>10.1016/j.cllc.2014.07.008  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Protocols<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Clinical Trials as Topic<br/>Drug Resistance, Neoplasm<br/>ErbB Receptors--genetics<br/>Gefitinib<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>Mutation--genetics<br/>Prospective Studies<br/>Protein Kinase Inhibitors--administration & dosage<br/>Quinazolines--administration & dosage<br/>Research Design<br/>Survival Analysis<br/>Withholding Treatment